

Authera AS established to translate Biological Insights into Innovative Design of Therapeutic Biologics

October 27- 2022, Oslo – Norway

Authera AS is a pre-clinical-stage biotechnology company dedicated to the discovery and development of novel therapeutic biologics.

The company's know-how is based on an in-depth molecular and cellular understanding of crucial biological processes, such as the dynamics of plasma half-life regulation involving interactions between the neonatal Fc receptor (FcRn) and its ligands, IgG antibodies and albumin.

While monoclonal IgG antibodies are the fastest growing class of therapeutic agents, albumin is increasingly explored as a carrier of biologics to tailor their biodistribution and plasma half-life. Authera AS has the expertise needed to guide and de-risk such product development towards clinical evaluation.

Authera AS has built a high-end and sophisticated technology platform. This platform can educate and fine-tune molecular designs to secure optimal FcRn-mediated cellular transport, which translates into favorable *in vivo* pharmacokinetic parameters in state-of-the-art mouse models.

“Authera is science-driven, as we are learning from nature. We take advantage of our deep biological insights into innovative design of protein-based biologics to improve their performance. Our strategy is to guide design, re-design and selection, with the aim to de-risk development programs. We strongly believe in partnership between academia, biotech and the pharma industry”, says co-founder Jan Terje Andersen.

Authera AS has initially chosen an organic growth strategy. The plan is to build an effective executive team and continuously expand partnerships and development of pre-clinical lead programs.

The company is located in *ShareLab, Oslo Science Park*, and is a spinout from *the Laboratory of Adaptive Immunity and Homeostasis at University of Oslo and Oslo University Hospital* (the institutions), headed by Professor Jan Terje Andersen. Co-founders are Professor emerita Inger Sandlie, Chief executive officer (CEO) Simone Mester and Chief scientific officer (CSO) Torleif Tollefsrud Gjølberg.

Key assets have been in-licensed from the Institutions technology transfer office *Inven2*, and from *Boston Children's Hospital* and its Technology & Innovation Development Office.

The Life Sciences Practice Group at Schjødt acts as legal counsel for Authera AS, and includes Tord Fondevik, Knut Sverre Skurdal Andresen, Jenny Nondal, Andreas Hundevadt and Anuschka Teresa Hager-Thoresen.

Holt & Paulsen AS is responsible for the identity and communication.

Authera AS is a member of *The Life Science Cluster*, which is a network for companies and organizations with more than 110 members across the health, technology, marine and agriculture sectors.